DE · SHL.DE · MEDICAL - DEVICES
Siemens Healthineers AG (SHL.DE) intrinsic value and stock valuation
$42.96as of 2026-11-21 · Mkt cap 38.83B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Siemens Healthineers AG DCF and intrinsic value
InvestorsCraft values SHL.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SHL.DE’s statements →
Siemens Healthineers AG Graham Number
Graham Number: $26.38d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $23.4B | $22.4B | $21.7B | $21.7B | $18B |
| Operating income | $3.44B | $3.3B | $2.44B | $3.06B | $2.78B |
| Net income | $2.14B | $1.94B | $1.51B | $2.04B | $1.73B |
| EPSd | $1.91M | $1.73M | $1.34M | $1.81M | $1.56M |
| Operating cash flow | $3.08B | $2.47B | $1.81B | $2.26B | $2.78B |
| Capital expenditure | -$-818M | -$-696M | -$-838M | -$-852M | -$-674M |
| Free cash flow | $2.27B | $1.77B | $971M | $1.4B | $2.11B |
| Total assets | $44.4B | $46.1B | $46.7B | $49.1B | $41.9B |
| Total debt | $15.1B | $16.2B | $16.7B | $16.7B | $14.3B |
| Net debt | $12.9B | $13.5B | $15B | $15.2B | $13B |
| Total equity | $18.1B | $18.2B | $18.1B | $19.9B | $16.1B |
| Cash and short-term investments | $2.18B | $2.68B | $1.64B | $1.44B | $1.32B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $23.4B | $22.4B | $21.7B | $21.7B | $18B |
| Cost of revenue | $14.3B | $13.9B | $14B | $13.6B | $11B |
| Gross profit | $9.03B | $8.47B | $7.71B | $8.14B | $6.95B |
| Research and development expenses | $1.96B | $1.92B | $1.87B | $1.79B | $1.55B |
| Selling, general and administrative expenses | $3.64B | $3.25B | $3.4B | $3.29B | $2.63B |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $5.6B | $5.17B | $5.27B | $5.07B | $4.18B |
| Cost and expenses | $19.9B | $19.1B | $19.2B | $18.7B | $15.2B |
| Interest income | $99M | $119M | $85M | $48M | $33M |
| Interest expense | $425M | $476M | $296M | $118M | $83M |
| Depreciation and amortization | $1.3B | $1.22B | $1.56B | $1.34B | $1.04B |
| Ebitda | $4.58B | $4.22B | $3.78B | $4.26B | $3.52B |
| Operating income | $3.44B | $3.3B | $2.44B | $3.06B | $2.78B |
| Total other income/expenses, net | -$-582M | -$-777M | -$-512M | -$-264M | -$-373M |
| Income before tax | $2.85B | $2.52B | $1.93B | $2.8B | $2.4B |
| Income tax expense | $685M | $564M | $403M | $746M | $658M |
| Net income | $2.14B | $1.94B | $1.51B | $2.04B | $1.73B |
| Weighted average shares outstanding | $1.12B | $1.12B | $1.12B | $1.12B | $1.1B |
| Weighted average diluted shares outstanding | $1.12B | $1.12B | $1.12B | $1.13B | $1.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.18B | $2.68B | $1.64B | $1.44B | $1.32B |
| Net receivables | $7.27B | $7.21B | $7.48B | $7.06B | $6.01B |
| Inventory | $4.14B | $4.18B | $4.29B | $4.01B | $3.18B |
| Total current assets | $14.1B | $14.4B | $14.1B | $13.4B | $10.8B |
| Property, plant and equipment, net | $4.71B | $4.48B | $4.21B | $4.27B | $3.71B |
| Goodwill and intangible assets | $23.6B | $24.7B | $25.8B | $27.8B | $25.5B |
| Long-term investments | $976M | $1.41B | $1.6B | $2.61B | $962M |
| Total non-current assets | $30.3B | $31.6B | $32.5B | $35.7B | $31.1B |
| Total assets | $44.4B | $46.1B | $46.7B | $49.1B | $41.9B |
| Accounts payable | $2.3B | $2.13B | $2.2B | $2.32B | $1.92B |
| Short-term debt | $3.72B | $2.75B | $4.4B | $2.84B | $2.15B |
| Deferred revenue | $3.64B | $3.63B | $3.63B | $3.75B | $2.9B |
| Total current liabilities | $12.6B | $11.6B | $13.4B | $12B | $10.1B |
| Long-term debt | $11.3B | $13.5B | $12.3B | $13.8B | $12.2B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $13.6B | $16.2B | $15.1B | $17.2B | $15.8B |
| Capital lease obligations | $505M | $533M | $449M | $468M | $481M |
| Total liabilities | $26.3B | $27.8B | $28.6B | $29.2B | $25.9B |
| Common stock | $1.13B | $1.13B | $1.13B | $1.13B | $1.13B |
| Retained earnings | $3.24B | $2.15B | $1.38B | $894M | -$-300M |
| Accumulated other comprehensive income (loss) | -$-1.68B | -$-522M | $340M | $2.36B | -$-369M |
| Total equity | $18.1B | $18.2B | $18.1B | $19.9B | $16.1B |
| Total investments | $976M | $1.41B | $1.6B | $2.61B | $962M |
| Total debt | $15.1B | $16.2B | $16.7B | $16.7B | $14.3B |
| Net debt | $12.9B | $13.5B | $15B | $15.2B | $13B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.14B | $1.94B | $1.51B | $2.04B | $1.73B |
| Depreciation and amortization | $1.3B | $1.22B | $1.56B | $1.34B | $1.04B |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-581M | -$-605M | -$-842M | -$-1.13B | $53M |
| Accounts receivable | -$-410M | -$-422M | -$-773M | -$-489M | -$-718M |
| Inventory | -$-76M | $39M | -$-453M | -$-481M | -$-22M |
| Accounts payable | $229M | -$-62M | -$-20M | $247M | $318M |
| Net cash provided by operating activities | $3.08B | $2.47B | $1.81B | $2.26B | $2.78B |
| Investments in property, plant and equipment | -$-818M | -$-696M | -$-838M | -$-852M | -$-674M |
| Acquisitions, net | -$-86M | $34M | -$-224M | -$-14M | -$-13.45B |
| Net cash used for investing activities | -$-906M | -$-666M | -$-1.07B | -$-868M | -$-14.14B |
| Common stock issued | $0.00 | $0.00 | $18M | $1M | $2.31B |
| Common stock repurchased | -$-301M | -$-10M | -$-421M | -$-309M | -$-255M |
| Dividends paid | -$-1.07B | -$-1.06B | -$-1.07B | -$-955M | -$-856M |
| Net cash used for financing activities | -$-2.59B | -$-1.3B | -$-380M | -$-1.4B | $12B |
| Net change in cash | -$-508M | $1.04B | $206M | $114M | $666M |
| Cash at end of period | $2.18B | $2.68B | $1.64B | $1.44B | $1.32B |
| Operating cash flow | $3.08B | $2.47B | $1.81B | $2.26B | $2.78B |
| Capital expenditure | -$-818M | -$-696M | -$-838M | -$-852M | -$-674M |
| Free cash flow | $2.27B | $1.77B | $971M | $1.4B | $2.11B |
Line items
Line items
Line items
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
- CEO
- Bernhard Montag
- Employees
- 72K
- Beta
- 0.80
Included in
Explore
Frequently asked questions
What is the intrinsic value of Siemens Healthineers AG (SHL.DE)?
InvestorsCraft does not currently publish an intrinsic value for SHL.DE. How the IC value is calculated.
Is SHL.DE undervalued?
InvestorsCraft does not publish an undervaluation signal for SHL.DE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.